The company plans to invest billions in a new drug manufacturing hub in Virginia, dedicated to chronic disease treatments, alongside additional facilities in California, Indiana, Maryland, Massachusetts, and Texas.
Susan Haigney
Advertisement
Susan Haigney is the lead editor of Pharmaceutical Technology and Biopharm International.
Articles by Susan Haigney
We spoke with Josh Hoerner, general manager of Purisys, which specializes in a small volume custom synthesis and specialized controlled substance manufacturing, to gain his perspective on FDA’s recommendations for acceptable intake limits for N-nitrosamine impurities.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on LCGC International
1
Navigating Adverse Reactions in GLP-1 Treatment
2
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
